(Q60301500)

1

0 references

Giridhar Tirucherai

2

0 references

Michael K Ahlijanian

3

0 references

Gerry Kolaitis

4

0 references

Clifford Bechtold

5

0 references

Michael Grundman

Alzheimer's & dementia (New York, N. Y.)

6

0 references

language of work or name

English

0 references

publication date

2018

0 references

published in

0 references

volume

4

0 references

page(s)

746-755

0 references

cites work

Looking for novel functions of tau.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

Tau stabilizes microtubules by binding at the interface between tubulin heterodimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

Roles of tau protein in health and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

Progressive Supranuclear Palsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

A Review of Treatment Options for Progressive Supranuclear Palsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

Current Research Therapeutic Strategies for Alzheimer's Disease Treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

Human secreted tau increases amyloid-beta production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

Tauopathies as clinicopathological entities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

The release and trans-synaptic transmission of Tau via exosomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

Extracellular truncated tau causes early presynaptic dysfunction associated with Alzheimer's disease and other tauopathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

Secretion of human tau fragments resembling CSF-tau in Alzheimer's disease is modulated by the presence of the exon 2 insert.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

Spreading of pathology in neurodegenerative diseases: a focus on human studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

Therapeutic strategies for the treatment of tauopathies: Hopes and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRCI.2018.10.007

Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies.

7 January 2021

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/30581980